Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a weight-loss drug also shield kidneys? new study explores retatrutide for CKD patients.

NCT ID NCT05936151

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether retatrutide, a medication being studied for weight loss, can help preserve kidney function in 146 adults who are overweight or obese and have chronic kidney disease (with or without type 2 diabetes). Participants received the drug or a placebo for about 31 weeks. The main goal was to measure changes in how well the kidneys filter blood. This is not a cure, but aims to control disease and prevent further kidney decline.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

146 people

The number who actually took part.

Started

Jul 2023

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²) * Have either * no T2D with an HbA1c \< 6.5% or * have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening. * Have been diagnosed with chronic kidney disease (CKD). Exclusion Criteria: * Have a self-reported change in body weight \>5 kilogram (kg) (11 pounds) within 90 days before screening. * Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin * Have a prior or planned surgical treatment for obesity * Have Type 1 Diabetes (T1D) * Have acute or chronic hepatitis * Have a history of malignant disease within 5 years before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD Overweight or obesity Type 2 diabetes

Contacts and locations

Locations

  • 9109-0126 Quebec Inc.

    Montreal, Quebec, H4N 2W2, Canada

  • Addenbrooke's Hospital

    Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom

  • Azienda Ospedaliera Universitaria Pisana

    Pisa, Tuscany, 56126, Italy

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

    Bergamo, 24127, Italy

  • Care Access - 801 South Power Road, Mesa

    Mesa, Arizona, 85206, United States

  • Catalina Research Institute, LLC

    Montclair, California, 91763, United States

  • Centricity Research Brampton Endocrinology

    Brampton, Ontario, L6S 0C6, Canada

  • Centro Cardiologico Monzino

    Milan, Milano, 20138, Italy

  • Circulate Cardiac & Vascular Centre

    Burlington, Ontario, L7M 1K9, Canada

  • City Hospital, Nottingham University Hospitals NHS Trust

    Nottingham, NG5 1PB, United Kingdom

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)

    Seville, 41003, Spain

  • Diex Recherche Joliette

    Joliette, Quebec, J6E 6A9, Canada

  • Dr. Anil K. Gupta Medicine Professional Corporation

    Toronto, Ontario, M9V 4B4, Canada

  • Endocrine Ips, Pllc

    Houston, Texas, 77079, United States

  • Fadia El Boreky Medicine

    Waterloo, Ontario, N2J 1C4, Canada

  • FutureMeds Teesside - Middlefield Centre

    Stockton-on-Tees, Durham County, TS19 8PE, United Kingdom

  • Futuremeds-Newcastle

    Newcastle, England, United Kingdom

  • Great Lakes Clinical Trials - Ravenswood

    Chicago, Illinois, 60640, United States

  • Headlands Research - Scottsdale

    Scottsdale, Arizona, 85260, United States

  • Hope Clinical Research, Inc.

    Canoga Park, California, 91303, United States

  • Hospital Clinico de Valencia

    Valencia, Valenciana, Comunitat, 46010, Spain

  • Hospital Universitario Doctor Peset

    Valencia, Valenciana, Comunitat, 46017, Spain

  • Indiana University Health University Hospital

    Indianapolis, Indiana, 46202, United States

  • Medical Advancement Centers of Arizona

    Tempe, Arizona, 85283, United States

  • NYU Langone Hospital - Long Island

    Mineola, New York, 11501, United States

  • North Middlesex Hospital

    London, London, City of, N18 1QX, United Kingdom

  • North York Diagnostic and Cardiac Centre

    North York, Ontario, M6B 3H7, Canada

  • Ospedale San Raffaele

    Milan, 20132, Italy

  • Palm Research Center Tenaya

    Las Vegas, Nevada, 89128, United States

  • Peninsula Research Associates

    Rolling Hills Estates, California, 90274, United States

  • Prime Health and Wellness/SKYCRNG

    Fayette, Mississippi, 39069, United States

  • Royal London Hospital

    London, England, E1 1BB, United Kingdom

  • Stouffville Medical Research Institute Inc.

    Stouffville, Ontario, L4A 1H2, Canada

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida, 34652, United States

  • Teradan Clinical Trials, LLC

    Brandon, Florida, 33511, United States

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa

    Chandler, Arizona, 85225, United States

  • Tranquility Research

    Webster, Texas, 77598, United States

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

  • Vascular Research Team

    Salford, Greater Manchester, M6 8HD, United Kingdom

  • Viacar Recherche Clinique

    Greenfield Park, Quebec, J4V 2G8, Canada

  • Victorium Clinical Research - Houston

    Houston, Texas, 77024, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.